Recent Updates
Recently added Catalysts
TAK Positive Sentiment

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026

Tuesday, September 22, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Takeda has announced that it will present new data from its oncology pipeline at the ESMO Congress in Madrid from October 23-27, 2026. The highlights include a late-breaking abstract on TAK-921 and presentations on TAK-928. This showcases Takeda's commitment to advancing cancer treatment options.

Market Sentiment Analysis

POSITIVE FACTORS

  • Takeda is showcasing significant progress in its oncology pipeline.
  • Late-breaking data on TAK-921 is expected to attract attention at ESMO.
  • The presentations may enhance understanding of solid tumor treatments.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+27%
120-day peak, hindsight
Typical move
1.4%
average across 15 past catalysts
Lead asset
SYR-472
Phase 3 · Diabetes Mellitus

Full Press Release Details

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain. Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*). Clinical and real-world analyses of ALUNBRIG®

Frequently Asked Questions

What is the focus of Takeda's presentation at ESMO 2026?

Takeda will present new data from its oncology pipeline, including TAK-921.

When will the ESMO Congress take place?

The ESMO Congress will occur from October 23-27, 2026.

What is TAK-921?

TAK-921, also known as arcotatug tavatecan, is part of Takeda's oncology pipeline.

Where is the ESMO Congress being held?

The ESMO Congress will be held in Madrid, Spain.

ShareAdd on Google
Tags: TAK Viatris Investor Conferences Healthcare oncology ESMO 2026 TAK-921 solid tumors
Last updated: Sep 22, 2026

Biotech snapshot

Lead asset
SYR-472Phase 3
Diabetes Mellitus →

Catalyst track record

+27%
best trade around TAK's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for TAK.

See every catalyst's timing & PoA →